Abstract
Current FDA guidance (Food and Drug Administration, Guidance for Industry: General considerations for pediatric pharmacokinetic studies for drugs and biological products. U.S. Department of Health and Human Services, Rockville, MD, November 1998) recommends administration of a fraction of an adult dose to pediatric patients based on mg/kg of bodyweight (BW) or mg/m2 of body surface area extrapolation of adult doses. However, children are not small adults, and it is recommended to use the systemic exposure [usually the area under the curve (AUC)] to guide the starting dose selection in pediatrics. Systemic exposure is typically the AUC observed at the therapeutic dose in adults. This approach implies the ability to predict the pharmacokinetics in pediatric patients. There are several techniques to predict the pharmacokinetics in children based on knowledge of the pharmacokinetics in adults. The preferred approach is physiologically based pharmacokinetic (PBPK) modeling. PBPK models account for developmental differences between adults and children of differing ages and incorporate known maturation and variability in clearance processes and distribution. However in cases when the PBPK approach is not possible, the recommendation is to use allometry. In the case of larger molecules (for example, with biological products), an mg/kg or allometric scaling approach may be appropriate, unless there is prior information that provides a more drug-specific way to calculate the starting dose. Additional information like the use of a safety factor and other approaches to estimate the starting dose in pediatrics will be described in this chapter.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
ICH Topic E 11 (2001) Clinical investigation of medicinal products in the paediatric population. CPMP/ICH/2711/99 (January 2001)
Food and Drug Administration (2003) Guidance for industry: exposure-response relationships – study design, data analysis, and regulatory applications. U.S. Department of Health and Human Services, Rockville (April 2003)
Food and Drug Administration (1998) Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. U.S. Department of Health and Human Services, Rockville (November 1998)
Kearns GL (2003) Developmental pharmacology – drug disposition, action and therapy in infants and children. NEJM 349(12):1157–1167
Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants. Part I. Clin Pharmacokinet 41(12):959–998
Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants. Part II. Clin Pharmacokinet 41(13):1077–1094
Bartelink IH (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45(11):1077–1097
Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42(10):883–908
Parrott N, Jones H, Paquereau N, Lave T (2005) Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 96:193–199
Edginton AN, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45(10):1013–1034
Parrott N, Davies B et al (2011) Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet 50(9):613–623
Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59(6):663–669
Björkman S (2004) Prediction of drug disposition in children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59(6):691–704
Khalil F, Laër S (2011) Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011, 907461, PMID:21716673
Hsien L (2010) Identifying paediatric needs in cardiology and the prediction of sildenafil exposure in children with pulmonary arterial hypertension. Inauguraldissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf (July 2010)
Haddad S, Restieri C, Krishnan K (2001) Characterization of age-related changes in bodyweight and organ weights from birth to adolescence in humans. J Toxicol Environ Health 64(6):453–464
Manolis E, Pons G (2009) Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol 68(4):493–501
Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47(4):231–243
Läer S et al (2005) Population pharmacodynamics in children with supraventricular tachycardia. JACC 46(7):1322–1330
Albers S, Meibohm B, Mir TS, Laër S (2007) Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 65(4):511–522
Booth BP (2007) Population pharmacokinetic-based bosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 47:101–111
Kuczmarski RJ, Ogden CL, Guo SS et al (2002) 2000 CDC growth charts for the United States: Methods and development. National Center for Health Statistics. Vital Health Stat 11(246):1–190
Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Ann Rev Pharmacol Toxicol 48:303–332
Anderson BJ, Meakin GH (2002) Scaling for size: some implications for paediatric anaesthesia dosing. Paed Anaesth 12:205–219
Crawford J, Terry M, Rourke G (1950) Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 5:783–790
Miminas DA (2007) A critical evaluation of the Lund and Browder chart. Wounds UK 3(3):58–66
Bailey BJR, Briars GL (1996) Estimating the surface area of the human body. Stat Med 15:1325–1332
Anderson BJ, Eliis JF (1999) Common errors of drug administration in infants. Causes and avoidance. Paediatr Drugs 1(2):93–107
Holford N (2010) Dosing in children. Clin Pharmacol Ther 87(3):367–370
Mahmood I (2006) Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 61(5):545–587
Ginsberg G et al (2002) Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 66:185–200
Scheuplein R, Charnley G, Dourson M (2002) Differential sensitivity of children and adults to chemical toxicity. I. Biological basis. Reg Toxicol Pharmacol 35:429–447
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Greig, G. (2014). How to Estimate the Dose to Be Given for the First Time to Pediatric Patients. In: Bar-Shalom, D., Rose, K. (eds) Pediatric Formulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 11. Springer, New York, NY. https://doi.org/10.1007/978-1-4899-8011-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-4899-8011-3_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4899-8010-6
Online ISBN: 978-1-4899-8011-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)